CULLINAN THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $18.9M | $0 |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $187.4M | $142.9M | $148.2M | $91.9M | $57.8M | $43.2M |
| SG&A Expense | — | $54.2M | $54.0M | $42.5M | $40.2M | $29.1M | $17.1M |
| Operating Income | — | $-241.6M | $-196.9M | $-191.1M | $144.6M | $-68.0M | $-60.3M |
| Operating Margin | — | — | — | — | — | -358.7% | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | $-219.9M | $-167.5M | $-169.2M | $151.3M | $-67.5M | — |
| Income Tax Expense | — | $0 | $117.0K | $-14.1M | $42.1M | $0 | — |
| Net Income | — | $-219.9M | $-167.4M | $-153.2M | $111.2M | $-65.6M | $-51.8M |
| Net Margin | — | — | — | — | — | -346.1% | — |
| EPS (Basic) | — | — | — | $-3.69 | $2.46 | $-1.52 | $-2.60 |
| EPS (Diluted) | — | — | — | $-3.69 | $2.38 | $-1.52 | $-2.60 |
| Shares Outstanding (Basic) | 60.5M | 60.2M | 58.5M | 41.6M | 45.2M | 43.1M | 29.8M |
| Shares Outstanding (Diluted) | 60.5M | 60.2M | 58.5M | 41.6M | 46.6M | 43.1M | 29.8M |
| Dividends Per Share | — | — | — | — | — | — | — |